Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Table 1 Baseline demographics and disease characteristics n (%)1
| Characteristic | Immediate treatment, n = 1552 | Placebo-deferred treatment, n = 52 | Overall, n = 2072 |
| Age, median (range) years | 49 (18-73) | 49 (23-69) | 49 (18-73) |
| < 65 yr | 142 (92) | 45 (87) | 187 (90) |
| ≥ 65 yr | 13 (8) | 7 (14) | 20 (10) |
| Male | 61 (39) | 23 (44) | 84 (41) |
| Race | |||
| Asian | 132 (85) | 45 (87) | 177 (86) |
| White | 23 (15) | 7 (14) | 30 (15) |
| Country | |||
| Mainland China | 119 (77) | 42 (81) | 161 (78) |
| Russia | 23 (15) | 7 (14) | 30 (15) |
| South Korea | 13 (8) | 3 (6) | 16 (8) |
| HCV RNA, median (range) log10 IU/mL | 6.78 (3.1-7.6) | 6.86 (5.6-7.6) | 6.79 (3.1-7.6) |
| ≥ 6 million IU/mL | 79 (51) | 31 (60) | 110 (53) |
| IL28B genotype | |||
| CC | 107 (69) | 34 (65) | 141 (68) |
| CT | 43 (28) | 17 (33) | 60 (29) |
| TT | 5 (3) | 1 (2) | 6 (3) |
| Cirrhosis | 19 (12) | 7 (14) | 26 (13) |
- Citation: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1361